These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 31433919)

  • 21. Serelaxin a novel treatment for acute heart failure.
    Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
    Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
    Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
    Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.
    Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ
    Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
    Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
    Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
    Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
    JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.
    Beldhuis IE; Ter Maaten JM; Figarska SM; Damman K; Pang PS; Greenberg B; Davison BA; Cotter G; Severin T; Gimpelewicz C; Felker GM; Filippatos G; Teerlink JR; Metra M; Voors AA
    Clin Res Cardiol; 2023 Jul; 112(7):901-910. PubMed ID: 36656377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.
    Packer M; O'Connor C; McMurray JJV; Wittes J; Abraham WT; Anker SD; Dickstein K; Filippatos G; Holcomb R; Krum H; Maggioni AP; Mebazaa A; Peacock WF; Petrie MC; Ponikowski P; Ruschitzka F; van Veldhuisen DJ; Kowarski LS; Schactman M; Holzmeister J;
    N Engl J Med; 2017 May; 376(20):1956-1964. PubMed ID: 28402745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
    Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
    Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
    Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF.
    Metra M; Davison BA; Gimpelewicz C; Carubelli V; Felker GM; Filippatos G; Greenberg BH; Hua TA; Liu Z; Pang PS; Ponikowski P; Severin TM; Voors AA; Wang Y; Cotter G; Teerlink JR
    Int J Cardiol; 2018 Feb; 253():91-96. PubMed ID: 29306479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
    Schmieder RE; Mitrovic V; Hengstenberg C
    Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
    Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR;
    JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
    Yu L; Cao L; Sun J; Li Z; Yao F; Zhou Y
    Medicine (Baltimore); 2018 Jun; 97(25):e11010. PubMed ID: 29923986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
    JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
    Ng TM; Goland S; Elkayam U
    Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.